Veru

Yahoo Finance • 11 months ago

Veru Announces Proposed Public Offering of Common Stock

Veru Inc. MIAMI, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of metabolic diseases, oncology and viral-induced acute r... Full story

Yahoo Finance • last year

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasing Fat Loss in a Phase 2b Obesity Clinical Study

-- In 5 clinical studies involving 968 older men and postmenopausal women with and without muscle wasting, enobosarm has demonstrated the ability to decrease fat mass, increase muscle mass, and improve muscle strength and physical function... Full story

Yahoo Finance • last year

Veru Reaches Agreement with FDA on New Phase 3 Clinical Trial for Sabizabulin for Broader Indication: Hospitalized Adult Patients with Any Type of Viral Acute Respiratory Distress Syndrome (ARDS)

--Reached agreement with FDA on single Phase 3 clinical trial design to expand treatment population to include all hospitalized adult patients with any type of virus induced ARDS including the “tripledemic viruses”: Influenza, RSV, and SAR... Full story

Yahoo Finance • last year

Veru to Participate in Fireside Chat at the 2023 Cantor Fitzgerald Global Healthcare Conference on September 28th, 2023

MIAMI, FL, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress s... Full story

Yahoo Finance • last year

Veru to Present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11th, 2023

MIAMI, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for metastatic breast cancer and for viral induced acute respiratory distress syndro... Full story

Yahoo Finance • last year

Veru Inc.’s Oncology Drug Research Program Partner, The University of Tennessee Health Science Center, Awarded Two New Federal Grants

Research grants from U.S. Department of Defense (DoD) and National Cancer Institute’s Research Project Grant (NCI R01) awarded to UTHSC to study new types of targeting agents for multiple cancer indications with significant unmet need Agg... Full story

Yahoo Finance • 2 years ago

Veru Reports Fiscal 2023 Second Quarter Financial Results

Agreement reached with FDA on confirmatory Phase 3 clinical trial design for sabizabulin treatment of hospitalized COVID-19 adult patients at high risk for acute respiratory distress syndrome (ARDS), including two planned interim efficacy... Full story

Yahoo Finance • 2 years ago

Veru Reaches Agreement with FDA on Confirmatory Phase 3 Clinical Trial for Sabizabulin Treatment of Hospitalized COVID-19 Adult Patients at High Risk for ARDS

Reached agreement with FDA on confirmatory Phase 3 clinical trial design in 408 subjects with primary endpoint of all-cause mortality at Day 60 Study to expand treatment population to include all WHO-4, WHO-5, and WHO-6 hospitalized adult... Full story

Yahoo Finance • 2 years ago

Veru Enters into Common Stock Purchase Agreement for Up to $100 Million with Lincoln Park Capital

MIAMI, FL, May 03, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of breast cancer and for SARS-CoV-2 and other viral ARDS-relate... Full story

Yahoo Finance • 2 years ago

Veru Enters Into Supply Agreement with Afaxys to Expand Access to FC2 Female Condom® in U.S. Public Health Sector

MIAMI, FL, April 19, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for oncology and SARS-CoV-2 and other viral ARDS-related diseases that has a commercial sexual heal... Full story

Yahoo Finance • 2 years ago

Veru Announces Preclinical Study Results that Demonstrate Sabizabulin Inhibits Poxviruses

Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome (ARDS) Company plans pre-Invest... Full story

Yahoo Finance • 2 years ago

Lifshitz Law PLLC Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Veru Inc. (NASDAQ: VERU), The Gap, Inc. (NYSE: GPS), and NeoGenomics, Inc. (NASDAQ: NEO)

NEW YORK, March 17, 2023 (GLOBE NEWSWIRE) -- Generac Holdings Inc. (NYSE: GNRC) Lifshitz Law PLLC announces investigation into possible securities laws violations and/or breaches of fiduciary duties in connection with alleged materiall... Full story

Yahoo Finance • 2 years ago

Gainey McKenna & Egleston Investigates Potential Claims On Behalf of Investors of Veru, Inc. (VERU)

NEW YORK, March 13, 2023 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that it is investigating whether the directors and/or officers of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU) breached their fiduciary duties of loy... Full story

Yahoo Finance • 2 years ago

Veru to Present at the Oppenheimer 33rd Annual Healthcare Conference

MIAMI, FL., March 07, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that Mitchell... Full story

Yahoo Finance • 2 years ago

Veru stock plummets toward 2 1/2-year low after FDA denies EUA request for COVID-19 treatment

Share of Veru Inc. (VERU) plunged 31.0% toward a 2 1/2-year low in premarket Friday, after the U.S. Food and Drug Administration turned down the biopharmaceutical company’s request for Emergency Use Authorization (EUA) for sabizabulin, its... Full story

Yahoo Finance • 2 years ago

Veru Provides FDA Update on Request for Emergency Use Authorization for Sabizabulin for Hospitalized COVID-19 Patients at High Risk for ARDS

MIAMI, FL, March 02, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, today announced that the U.S.... Full story

Yahoo Finance • 2 years ago

Investigation Alert GRNC, VERU, GPS, UIS: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors’ Losses?

SAN DIEGO, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Generac Holdings Inc.(NYSE: GNRC) Johnson Fistel, LLP is investigating potential claims on behalf Generac Holdings Inc. (NYSE: GNRC) against certain of its officers and directors. If you... Full story

Yahoo Finance • 2 years ago

Lawsuit for Investors who lost money with shares of Veru Inc. (NASDAQ: VERU) announced by Shareholders Foundation

SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- The Shareholders Foundation, Inc. announces that a lawsuit is pending for certain investors in shares of Veru Inc. (NASDAQ: VERU). Investors who purchased shares of Veru Inc. (NASDAQ: VERU) p... Full story

Yahoo Finance • 2 years ago

DEADLINE ALERT for VERU and NEO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the... Full story

Yahoo Finance • 2 years ago

VERU 3-DAY DEADLINE ALERT: Hagens Berman Encourages Veru Inc. (VERU) Investors with Significant Losses to Contact Firm’s Attorneys Before Feb. 6th Deadline in Securities Class Action

SAN FRANCISCO, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Hagens Berman urges Veru Inc. (NASDAQ: VERU) investors with significant losses to submit your losses now. Class Period: May 11, 2022 – Nov. 9, 2022 Lead Plaintiff Deadline: Feb. 6, 2023... Full story